Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Intellia Thera CS (NQ: NTLA)
16.16 USD  -1.46 (-8.29%)
Official Closing Price  /  Updated: 4:48 PM EDT, Mar 22, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 556,954
Open 17.62
Bid (Size) 16.05 (1)
Ask (Size) 17.80 (3)
Prev. Close 17.62
Today's Range 16.12 - 17.64
52wk Range 11.03 - 32.95
Shares Outstanding 43,089,810
Dividend Yield N/A
Performance
YTD
+17.96%
+17.96%
1 Month
+17.96%
+17.96%
3 Month
+17.78%
+17.78%
6 Month
-48.71%
-48.71%
1 Year
-31.12%
-31.12%
Top News
More News
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results
Intellia Therapeutics, Inc.® (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology in both in vivo and ex vivo applications, today... Read More
from GlobeNewswire News Releases
Research Report Identifies Norfolk Southern, DENTSPLY SIRONA, Healthcare Realty Trust, PTC, Intellia Therapeutics, and El Paso Electric with Renewed Outlook — Fundamental Analysis, Calculating Forward
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Norfolk Southern... Read More
from GlobeNewswire News Releases
More News
Read More
Intellia Therapeutics Names Fred Cohen, M.D., to Board of Directors
from GlobeNewswire News Releases
CORRECTED-Intellia CEO not involved in Starboard's Bristol-Myers board challenge
category companyNews
from Reuters: Company News
We Did The Math XBI Can Go To $129
category ETFs
from ETF Channel
A Specialty Biotech ETF Strengthens on Optimism Over CRISPR Advancements
category EDIT , Innovative ETFs Channel , Health Care , and 7 more.
from ETF Trends
5 Top Gene-Editing Stocks for 2019
category Market News , SGMO , CLLS , and 3 more.
from Motley Fool
Intellia CEO not involved in Starboard's Bristol-Myers board challenge
category companyNews
from Reuters: Company News
Gene therapy stocks surge on Roche-Spark deal
category NTLA , Earnings , Medical Products , and 16 more.
from MarketWatch
Intellia Therapeutics Stock Sees Short Interest Jump 11%
category Stocks
from Market News Video
Analysts Expect SPTM To Hit $38
category ETFs
from ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X